ZA988009B - Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy. - Google Patents

Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy.

Info

Publication number
ZA988009B
ZA988009B ZA9808009A ZA988009A ZA988009B ZA 988009 B ZA988009 B ZA 988009B ZA 9808009 A ZA9808009 A ZA 9808009A ZA 988009 A ZA988009 A ZA 988009A ZA 988009 B ZA988009 B ZA 988009B
Authority
ZA
South Africa
Prior art keywords
administering
methods
receptor antagonist
dopamine agonist
ampa receptor
Prior art date
Application number
ZA9808009A
Other languages
English (en)
Inventor
Bertrand Leo Chenard
John Timothy Greenamyre
Frank Samuel Menniti
Jr Willard Mckowan Welch
Original Assignee
Pfizer Prod Inc
John Timothy Greenamyre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, John Timothy Greenamyre filed Critical Pfizer Prod Inc
Publication of ZA988009B publication Critical patent/ZA988009B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9808009A 1997-09-05 1998-09-02 Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy. ZA988009B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5796597P 1997-09-05 1997-09-05

Publications (1)

Publication Number Publication Date
ZA988009B true ZA988009B (en) 2000-03-22

Family

ID=22013812

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9808009A ZA988009B (en) 1997-09-05 1998-09-02 Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy.

Country Status (11)

Country Link
US (1) US20010034345A1 (fr)
EP (1) EP0900567A3 (fr)
JP (1) JP3547624B2 (fr)
KR (1) KR100457756B1 (fr)
AU (1) AU8319398A (fr)
CA (1) CA2246560C (fr)
HU (1) HUP9802022A2 (fr)
IL (1) IL125953A0 (fr)
NZ (1) NZ331636A (fr)
TW (1) TW490304B (fr)
ZA (1) ZA988009B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20005049U1 (de) * 2000-03-20 2000-05-18 Dewert Antriebs- und Systemtechnik GmbH & Co KG, 32278 Kirchlengern Elektromotorische Antriebseinheit
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
EP1604654A1 (fr) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
AU2006234627C1 (en) * 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
ES2402376T3 (es) * 2006-04-06 2013-05-03 Nupathe Inc. Implantes para el tratamiento de estados asociados con dopamina
WO2008041118A2 (fr) 2006-10-04 2008-04-10 Pfizer Products Inc. Dérivés de pyrido[4,3-d]pyrimidin-4(3h)-one utilisés en tant qu'antagonistes du récepteur calcique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
WO1992013535A1 (fr) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Quinazolones substituees a activite anticonvulsivante
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
KR100375155B1 (ko) * 1996-05-15 2003-08-19 화이자 인코포레이티드 신규한2,3-이치환된-4(3에이치)-퀴나졸리논

Also Published As

Publication number Publication date
AU8319398A (en) 1999-03-18
TW490304B (en) 2002-06-11
NZ331636A (en) 2000-08-25
JPH11139991A (ja) 1999-05-25
KR100457756B1 (ko) 2005-04-14
EP0900567A2 (fr) 1999-03-10
JP3547624B2 (ja) 2004-07-28
CA2246560C (fr) 2002-12-17
US20010034345A1 (en) 2001-10-25
CA2246560A1 (fr) 1999-03-05
IL125953A0 (en) 1999-04-11
HUP9802022A2 (hu) 1999-05-28
EP0900567A3 (fr) 2001-05-02
KR19990029528A (ko) 1999-04-26
HU9802022D0 (en) 1998-10-28

Similar Documents

Publication Publication Date Title
ZA988139B (en) Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy.
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
WO2004058717A8 (fr) Derives d'isoquinolinone et leur utilisation comme agents therapeutiques
PL332432A1 (en) Oxadiazoles, method of obtaining them as well as their application as therapeutic agents
WO2001005763A3 (fr) Composes possedant une activite sur les recepteurs muscariniques
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
AU2003261251A1 (en) Methods of delivering therapeutic agents
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
SG165998A1 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
AU8912898A (en) Methods for inhibiting detrimental side-effects due to gnrh or gnrh agonist administration
MXPA03009595A (es) Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos.
WO2001007028A3 (fr) Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate
ZA988009B (en) Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy.
IL143385A0 (en) 5ht1 antagonists for antidepressant therapy
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
AU8553898A (en) Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system
GB9811312D0 (en) Method of treatment with an angiotensin II antagonist
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
CA2299400A1 (fr) Methode de traitement de dyskinesies liees a une maladie ou provoquees par l'absorption de medicaments
WO2000076500A3 (fr) Compound for use as a medicament for treatment of disorders involving bronchocontraction
AU2002300534A1 (en) Methods of Administering an AMPA Receptor Antagonist to Treat Dyskinesias Associated with Dopamine Agonist Therapy
AU2204701A (en) Formulations of adenosine a1 agonists
WO2002039996A3 (fr) Therapie combinee contre des tumeurs comprenant du phosphate d'estramustine et des agonistes ou antagonistes de lh-rh
DE60102481D1 (en) Purinriboside als antiarrhythmika